2026– date –
-
Samsung, SK Hynix Eye Honam Region in South Korea for First Advanced Packaging Fabs Amid Soaring AI Memory Demand; Amkor Plans $980M Expansion
The Elec Inc. South Korea Overview Samsung Electronics and SK Hynix are considering establishing their first advanced semiconductor packaging plants in South Korea's Honam region to meet surging AI infrastructure demand. Samsung is weigh... -
Novo Nordisk’s Zenagamutide: Dual GLP-1/Amylin Agonist Delivers Significant Metabolic Gains in Type 2 Diabetes
Healio デンマーク Overview Novo Nordisk's novel unimolecular GLP-1/amylin receptor agonist, zenagamutide, has demonstrated significant reductions in HbA1c and body weight in adults with type 2 diabetes during its Phase 2 clinical trial. ... -
Precision Science Fuels Biopharma M&A Surge: Q1 2026 Hits $65B+, Marking Industry’s ‘Full Recovery’
BioSpace / PwC, Pharmaceutical Technology / PwC USA Overview PwC's latest report declares the biopharma ecosystem 'fully recovered,' with Q1 2026 M&A deal values exceeding $65 billion, marking the largest quarter since 2020. This rob... -
FDA Grants Accelerated Approval to AVLAYAH, a BBB-Penetrating Biologic, Ushering in a New Era for Brain Drug Delivery
Drug Delivery Leader USA Overview On March 25, 2026, the FDA granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), the first biologic engineered to traverse the blood-brain barrier (BBB). This landmark decision, following dec... -
Recipharm Infuses Millions into US Sterile Fill-Finish, Bolstering Advanced Therapy Manufacturing
Recipharm (プレスリリース), Fierce Pharma スウェーデン Overview Global CDMO Recipharm is making a multi-million dollar strategic investment to significantly enhance its US sterile fill-finish capabilities, addressing the surging demand f... -
Closing the Innovation Gap: Early CMC Risk Management and Robust Conjugation Strategies for ADCs and AOCs
Industry Publication Unknown Overview As Antibody-Drug Conjugates (ADCs) and Oligonucleotide-Drug Conjugates (AOCs) rapidly expand beyond oncology, early identification of Chemistry, Manufacturing, and Controls (CMC) risks and establishi... -
Hongene Biotech Leverages Chemoenzymatic Ligation to Scale CRISPR sgRNA Manufacturing
Industry Publication / Hongene Biotech Unknown Overview Hongene Biotech is pioneering a chemoenzymatic ligation technology to address the critical scalability challenges in producing single-guide RNA (sgRNA) for CRISPR gene editing. This... -
ChemCopilot’s Generative AI Translates Natural Language to SMILES, Automating Molecular Design
ChemCopilot Unknown Overview ChemCopilot has launched a groundbreaking generative AI model for molecular design, capable of translating natural language prompts into stable SMILES strings. This innovative system automates the entire work... -
Oral GLP-1 Agonist Elecoglipron Achieves Landmark 11.8% Weight Loss and Superior Glycemic Control in Phase 2 Trial
News-Medical.Net 他 USA Overview The oral GLP-1 receptor agonist elecoglipron delivered compelling results in its Phase 2b SOLSTICE clinical trial, achieving up to 11.8% dose-dependent body weight reduction and significantly improving gl... -
Efficient Prime Editing In Vivo and In Vitro Demonstrated with Lipid Nanoparticles: High Efficacy, Low Off-Target Effects
PubMed International Overview Recent research reports the development of an optimized platform for prime editing using lipid nanoparticles (PE-LNP), demonstrating high gene editing efficiency in vivo. This LNP-based system offers a compe...
